Protagenic Therapeutics, Inc.\new annual stock-based compensation
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2026
Protagenic Therapeutics, Inc.\new Stock-Based Compensation Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's stock-based compensation was $418,589 for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $418,589 | — | — |
| 2024 | 2024-12-31 | $923,139 | $256,311 | +38.44% |
| 2023 | 2023-12-31 | $666,828 | −$197,853 | −22.88% |
| 2022 | 2022-12-31 | $864,681 | −$654,075 | −43.07% |
| 2021 | 2021-12-31 | $1.5M | −$135,998 | −8.22% |
| 2020 | 2020-12-31 | $1.7M | $856,993 | +107.42% |
| 2019 | 2019-12-31 | $797,761 | −$332,310 | −29.41% |
| 2018 | 2018-12-31 | $1.1M | $241,790 | +27.22% |
| 2017 | 2017-12-31 | $888,281 | $342,147 | +62.65% |
| 2016 | 2016-12-31 | $546,134 | $67,505 | +14.10% |
| 2015 · Dec 31 | 2015-12-31 | $478,629 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $0 | −$275,000 | — |
| 2014 | 2014-06-30 | $275,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly stock-based compensation
Q3.11
Q3.11
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $67,012 | −$58,115 | −46.44% |
| Q4 2026 | 2026-03-31 | $91,652 | −$144,362 | −61.17% |
| Q3 2026 | 2025-12-31 | $95,942 | −$149,494 | −60.91% |
| Q2 2026 | 2025-09-30 | $105,868 | −$144,535 | −57.72% |
| Q1 2026 | 2025-06-30 | $125,127 | −$140,312 | −52.86% |
| Q4 2025 | 2025-03-31 | $236,014 | $74,153 | +45.81% |
| Q4 2024 | 2024-12-31 | $245,436 | $78,729 | +47.23% |
| Q3 2024 | 2024-09-30 | $250,403 | $83,696 | +50.21% |
| Q2 2024 | 2024-06-30 | $265,439 | $98,732 | +59.22% |
| Q1 2024 | 2024-03-31 | $161,861 | −$4,846 | −2.91% |
| Q4 2023 | 2023-12-31 | $166,707 | −$31,981 | −16.10% |
| Q3 2023 | 2023-09-30 | $166,707 | −$47,972 | −22.35% |
| Q2 2023 | 2023-06-30 | $166,707 | −$48,828 | −22.65% |
| Q1 2023 | 2023-03-31 | $166,707 | −$69,072 | −29.30% |
| Q4 2022 | 2022-12-31 | $198,688 | −$19,478 | −8.93% |
| Q3 2022 | 2022-09-30 | $214,679 | −$16,970 | −7.33% |
| Q2 2022 | 2022-06-30 | $215,535 | −$507,431 | −70.19% |
| Q1 2022 | 2022-03-31 | $235,779 | −$110,196 | −31.85% |
| Q4 2021 | 2021-12-31 | $218,166 | −$193,437 | −47.00% |
| Q3 2021 | 2021-09-30 | $231,649 | −$259,950 | −52.88% |
| Q2 2021 | 2021-06-30 | $722,966 | $331,850 | +84.85% |
| Q1 2021 | 2021-03-31 | $345,975 | −$14,461 | −4.01% |
| Q4 2020 | 2020-12-31 | $411,603 | — | — |
| Q3 2020 | 2020-09-30 | $491,599 | $352,533 | +253.50% |
| Q2 2020 | 2020-06-30 | $391,116 | $130,556 | +50.11% |
| Q1 2020 | 2020-03-31 | $360,436 | −$90,705 | −20.11% |
| Q3 2019 | 2019-09-30 | $139,066 | −$122,072 | −46.75% |
| Q2 2019 | 2019-06-30 | $260,560 | −$2,588 | −0.98% |
| Q1 2019 | 2019-03-31 | $451,141 | $106,494 | +30.90% |
| Q4 2018 | 2018-12-31 | $261,138 | $27,564 | +11.80% |
| Q3 2018 | 2018-09-30 | $261,138 | $107,308 | +69.76% |
| Q2 2018 | 2018-06-30 | $263,148 | $117,607 | +80.81% |
| Q1 2018 | 2018-03-31 | $344,647 | −$10,689 | −3.01% |
| Q4 2017 | 2017-12-31 | $233,574 | $138,006 | +144.41% |
| Q3 2017 | 2017-09-30 | $153,830 | −$56,871 | −26.99% |
| Q2 2017 | 2017-06-30 | $145,541 | $8,584 | +6.27% |
| Q1 2017 | 2017-03-31 | $355,336 | $252,428 | +245.29% |
| Q4 2016 | 2016-12-31 | $95,568 | −$24,089 | −20.13% |
| Q3 2016 | 2016-09-30 | $210,701 | −$67,194 | −24.18% |
| Q2 2016 | 2016-06-30 | $136,957 | $80,681 | +143.37% |
| Q1 2016 · Mar 31 | 2016-03-31 | $102,908 | $78,107 | +314.93% |
| Q4 2015 | 2015-12-31 | $119,657 | — | — |
| Q1 2016 · Sep 30 | 2015-09-30 | $277,895 | — | — |
| Q4 2015 | 2015-06-30 | $56,276 | — | — |
| Q3 2015 | 2015-03-31 | $24,801 | — | — |
| Q3 2011 · Sep 30 | 2011-09-30 | $33,000 | −$192,000 | −85.33% |
| Q3 2011 · Sep 30 | 2010-09-30 | $225,000 | — | — |
Protagenic Therapeutics, Inc.\new stock-based compensation trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's stock-based compensation increased from $275,000 to $418,589, a change of $143,589. The latest reported quarter, Q1 2027, shows $67,012.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗